Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon

Menú

Buscar estudios clínicos de BMS
Ícono de BMS, studio Reclutando

Recruiting

ID del estudio CA258-0001  |   NCT07325136

A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination With Nivolumab in Participants With Relapsed/Refractory Small Cell Lung Cancer

Resumen

  • Phase 1/Phase 2
  • Ícono de género masculino y femenino
  • 18+
  • 7
  • Ícono de BMS, studio Reclutando
    Recruiting

Descripción general

The purpose of this study is to assess the safety and tolerability of BMS-986525 alone and in combination with Nivolumab in participants with Relapsed/Refractory Small Cell Lung Cancer

Imprimir Imprimir
Email Correo electrónico

Centro de reclutamiento más cercano

Criterios clave de elegibilidad

Criterios de inclusión

Criterios de inclusión Icon
  • Participants must have histologically or cytologically documented relapsed/refractory small cell lung cancer (R/R-SCLC).
    1. Participants must have received at least 1 platinum-based chemotherapy regimen as per locally approved drug labels and institutional guidelines.
      1. In countries where standard of care first line systemic treatment includes platinum containing chemotherapy in combination with anti-PD-(L)1 therapy, it is required that participants have progressed on, are ineligible for or not have access to an anti-PD
        1. (L)1 therapy.

          Criterios de exclusión

          Criterios de exclusión Icon
          • Participants must not have any untreated CNS metastases.
            1. Participants must not have an active, known or suspected autoimmune disease.
              1. Participants must not have had a prior organ or tissue allograft.
                Información Adicional *
                • Other protocol-defined Inclusion/Exclusion criteria apply.

                  Opciones de tratamiento

                  Brazos del estudio

                  INTERVENCIÓN ASIGNADA

                  Brazos del estudio

                  Experimental: Part 1A: BMS-986525 Monotherapy Dose Escalation

                  INTERVENCIÓN ASIGNADA
                  • Drug: BMS-986525

                  Brazos del estudio

                  Experimental: Part 1B: BMS-986525 Combination with Nivolumab Dose Escalation

                  INTERVENCIÓN ASIGNADA
                  • Drug: BMS-986525, Nivolumab

                  Brazos del estudio

                  Experimental: Part 2A: BMS-986525 Monotherapy Dose Expansion

                  INTERVENCIÓN ASIGNADA
                  • Drug: BMS-986525

                  Brazos del estudio

                  Experimental: Part 2B: BMS-986525 Combination with Nivolumab Dose Expansion

                  INTERVENCIÓN ASIGNADA
                  • Drug: BMS-986525, Nivolumab
                  Dé el primer paso para ver si es compatible con un estudio clínico - Verifique su elegibilidad
                  Verifique su elegibilidad
                  Responda algunas preguntas sobre su salud para ver si puede ser compatible con este enstudio.
                  Compatibilizar con un estudio
                  Si es compatible, haga clic en el estudio para ver la lista de ubicaciones de los centros del estudio.
                  Seleccione una ubicación del centro del estudio
                  Seleccione una ubicación del centro del estudio que sea conveniente para usted
                  Registrarse
                  Proporcione sus datos de contacto para que el centro del estudio se comunique con usted.

                  Ayúdenos a mejorar su experiencia en el sitio web. Comparta sus comentarios con nuestro equipo en BMS Clinical Trials para mejorar su experiencia y la de los demás. Gracias